1-4 of 4
August Salvado, MD
Close
Sort by
Journal Articles

A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML).

Anjali S. Advani, MD, Ronald Sobecks, MD, Mikkael A. Sekeres, MD, Ed Copelan, MD, Jennifer Bates, Barbara Tripp, RN, August Salvado, MD, Matt Kalaycio, MD
Journal: Blood
Blood (2007) 110 (11): 906.
https://doi.org/10.1182/blood.V110.11.906.906
Published: 2007
Journal Articles

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, Steven Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2005) 106 (11): 1830.
https://doi.org/10.1182/blood.V106.11.1830.1830
Published: 2005
Journal Articles

Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial.

Vesna Najfeld, Ph.D., Richard T. Silver, MD, Ronald Hoffman, MD, August Salvado, MD, Rona Weinberg, Ph.D., Steven Fruchtman, MD
Journal: Blood
Blood (2004) 104 (11): 2431.
https://doi.org/10.1182/blood.V104.11.2431.2431
Published: 2004
Journal Articles

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia, MD, Steven Kornblau, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2004) 104 (11): 2738.
https://doi.org/10.1182/blood.V104.11.2738.2738
Published: 2004